We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01617395
Recruitment Status : Recruiting
First Posted : June 12, 2012
Last Update Posted : November 6, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:


- Research shows that both genes and the environment influence a person s risk for getting multiple sclerosis (MS). However, it is not possible to accurately predict who will develop MS. Researchers want to study people with MS and their family members. They have developed a Genetic and Environmental Risk Score for MS. This score combines information from a person's medical history and genes. It also includes environmental factors that may be related to developing MS. This study will test this risk score to see if it can help predict who will develop MS.


- To evaluate a score for genetic and environmental risk factors that may help predict whether a person will develop MS.


  • Individuals at least 18 years of age who have MS.
  • Individuals between 18 to 50 years of age who are the parent, brother, sister, or child of a person with MS.


  • People with MS will allow researchers to look at their personal and medical data. These data will have been collected in other MS-related studies.
  • Relatives of people with MS will fill out a questionnaire and give blood and saliva samples. They will fill out the questionnaire again one year later.
  • Some relatives will have additional optional testing. These tests will include a physical exam and imaging studies. There may also be other tests. These tests may be repeated every 1 to 5 years for 20 years.

Condition or disease
Multiple Sclerosis

  Show Detailed Description

Study Design

Study Type : Observational
Estimated Enrollment : 2080 participants
Time Perspective: Other
Official Title: Integrating Genetic and Environmental Risk Scores Into an Algorithm to Predict Multiple Sclerosis Susceptibility
Study Start Date : May 30, 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :
  1. The primary outcome is diagnosis of MS according to the 2010 revisions to the McDonald criteria.

Secondary Outcome Measures :
  1. Secondary outcome measures include development of MS-like abnormalities on brain imaging studies, abnormalities on laboratory testing, and clinical symptoms and signs.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

GEMS cohort (target n equals 1000)

  • First-degree relative (parent, sibling, or child) of a self-reported MS patient.
  • Age 18-50, inclusive, at the time of enrollment into the overall GEMS study.
  • Willingness to be contacted regarding additional follow-up procedures.
  • Cross-sectional subcohort (target n equal 150):

    • Referred by Harvard as having a genetic and environmental risk score (GERS), defined in Section 4.1.1, in the top or bottom 20% of the overall GEMS study.
  • NINDS Longitudinal subcohort (target n equal 100):

    • Ages 18-40, inclusive.
    • Referred by Harvard as having a GERS in the top 20% of the overall GEMS study.
    • Willing to undergo additional study procedures at the NIH for up to 20 years, with planned follow-up every year for participants between ages 18 and 25, every 2 years for participants between ages 26 and 30, and every 5 years for participants between ages 31 and 40.
    • Relative enrolled in NIH study with confirmation of MS diagnosis.

MS patient cohort (target n=1000):

  • MS patients (NIH)

    • Co-enrolled in another Neuroimmunology Clinic natural history protocol.
    • Diagnosis confirmed at NIH.
    • Age 18 or older.
  • MS patient (non-NIH)

    • First-degree relative (parent, sibling, or child) of an existing GEMS participant.
    • Able and willing to send medical records associated with their MS diagnosis to NIH.
  • Healthy volunteer cohort (target n=80)

    • Age 18-50, inclusive.
    • No known first-degree relative (parent, sibling, or child) with MS.
  • All cohorts

    • Able to give informed consent.


GEMS cohort

-Diagnosis of MS.

Cross-sectional and NINDS longitudinal subcohorts

  • Contraindications to MRI scanning.
  • Diagnosis of another central nervous system disease disease (CNS neoplasm, known cerebrovascular disease, known CNS degenerative diseases, or known CNS inflammatory diseases) at the time enrollment into the study.
  • MS cohort (both)

  • Healthy volunteer cohort

    • Diagnosis of MS or another central nervous system (CNS neoplasm, cerebrovascular disease CNS degenerative diseases, or CNS inflammatory diseases) or a systemic disease that would interfere with the aims of this study.
    • Contraindications to MRI scanning.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01617395

Contact: Rosalind Hayden, R.N. (301) 827-9002 haydenre@ninds.nih.gov
Contact: Daniel S Reich, M.D. (301) 496-1801 reichds@ninds.nih.gov

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010    prpl@mail.cc.nih.gov   
Sponsors and Collaborators
National Institutes of Health Clinical Center (CC)
National Institute of Neurological Disorders and Stroke (NINDS)
Principal Investigator: Daniel S Reich, M.D. National Institutes of Health Clinical Center (CC)
More Information

Additional Information:
Responsible Party: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT01617395     History of Changes
Other Study ID Numbers: 120122
First Posted: June 12, 2012    Key Record Dates
Last Update Posted: November 6, 2017
Last Verified: October 31, 2017

Keywords provided by National Institutes of Health Clinical Center (CC):
Multiple Sclerosis
Magnetic Resonance Imaging (MRI)

Additional relevant MeSH terms:
Multiple Sclerosis
Disease Susceptibility
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Disease Attributes